Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

, ,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Compass Pathways Psilocybin Patent Upheld

Compass Pathways Psilocybin Patent Upheld

,
Compass Pathways scores a major victory in their bid to patent Comp 360, a proprietary formulation of psilocybin.

Cybin Acquires Entheon’s DMT Trial, Numi’s Novamind Acq. Complete, Bad News for MindMed and More

This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and more! Cybin Acquires DMT Clinical Study from Entheon…
Psychedelic Business Spotlight - June 17

Psychedelic Business Spotlight – June 17

, ,
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
The Four Psychedelics ETFs Capturing Investor Attention

The Four Psychedelics ETFs Capturing Investor Attention

,
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success will vary.

Psychedelic Business Spotlight – June 10

,
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and more!

Psychedelic Business Spotlight – June 3

,
This week in psychedelic business news: Cybin moves towards clinical trials; Braxia releases data on treating depression with psilocybin; Clearmind files for a new patent; and much more!

Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview

In today's episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA. ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy. The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy. This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend. In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed. To learn more about ATMA, visit: https://www.atmajourney.com/ To learn more about Catalyst, visit: https://catalystpresents.ca/ #psychedelics #therapy #magicmushrooms
5 Next-Generation Psychedelics Entering Clinical Trials This YearShutterstock

5 Next-Generation Psychedelics Entering Clinical Trials This Year

,
Modernized psychedelic medicine is coming, whether you like it or not, so here are five of the most exciting next-generation psychedelics on the horizon.

Psychedelic Business Spotlight – May 27

,
This week in psychedelic business news: New patents; another Health Canada SAP Approval; and legal psilocybin rules for Oregon.